Infectious Diseases Department, Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Reina Sofía University Hospital of Córdoba, University of Córdoba, Córdoba, Spain.
CIBERINFEC, ISCIII - CIBER of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain.
Front Public Health. 2023 Feb 2;11:1092960. doi: 10.3389/fpubh.2023.1092960. eCollection 2023.
The burden hepatitis C infection in people with history or current drug use suppose a high risk of hepatic complications and transmission infectious disease. This population is poor linked to heath system and is difficult to achieve them and support treatment because they have high rates of lost follow-up. Our aim was to evaluate an intervention for the diagnosis and treatment of chronic hepatitis C and HIV in this population.
Six-hundred and eighty-three people attended in Drugs and Addictions Centers (DAC) were asked to participate in health counseling and provide blood sample for test HCV, HIV, and syphilis from April 2019 to June 2020. Totally 556 subjects were surveyed and tested. All of them were assigned to a patient navigation program to improve health education and linking to the sanitary system. Hepatitis C infection patients were evaluated in an ampliated medical consult to evaluate hepatic stage with transient liver elastography and initiated Direct Acting Antivirals to achieve Sustained Viral Response.
Of the 556 patients who agreed to participate in the study, 33 (5.9%) had active HCV infection. Of the 33 patients infected with HCV, three were lost to follow-up once the diagnosis of HCV infection was made. Twenty-eight patients (93.3%) completed treatment and 26 achieved Sustained Viral Response (78.8%). Of the 30 patients, seven (23.3%) had advanced fibrosis, and of these, four (16.6%) had liver cirrhosis. One of the cirrhotic patients had hepatic space-occupying lesions at the baseline evaluation and was diagnosed with hepatocarcinoma.
Our study suggests that the implementation of strategies based on personalized intervention models can contribute to the control of HCV infection in DAC users.
有吸毒史或现吸毒人群的丙型肝炎感染负担意味着他们有发生肝脏并发症和传染病传播的高风险。该人群与卫生系统联系薄弱,难以实现并支持治疗,因为他们有很高的失访率。我们的目的是评估在该人群中诊断和治疗慢性丙型肝炎和 HIV 的干预措施。
2019 年 4 月至 2020 年 6 月,我们邀请参加毒品和成瘾中心 (DAC) 的 683 人参加健康咨询,并提供血液样本检测 HCV、HIV 和梅毒。共调查了 556 名受试者。所有受试者均被分配到患者导航计划,以改善健康教育并与卫生系统联系。丙型肝炎感染患者进行了扩大的医疗咨询,以通过瞬时肝脏弹性成像评估肝脏阶段,并启动直接作用抗病毒药物以实现持续病毒学应答。
在同意参与研究的 556 名患者中,有 33 名(5.9%)患有活动性丙型肝炎感染。在感染 HCV 的 33 名患者中,有 3 名在诊断出 HCV 感染后失访。28 名患者(93.3%)完成了治疗,26 名患者达到了持续病毒学应答(78.8%)。在 30 名患者中,有 7 名(23.3%)有进展性纤维化,其中 4 名(16.6%)有肝硬化。一名肝硬化患者在基线评估时出现肝占位性病变,被诊断为肝癌。
我们的研究表明,实施基于个性化干预模型的策略有助于控制 DAC 用户中的 HCV 感染。